bluebird bio Licenses Lentiviral Vector Patent Rights for Development and Commercialization of Cell…
bluebird bio announced that it has entered into a worldwide license agreement around its proprietary lentiviral vector platform with Novartis Pharma AG.
“bluebird bio is a pioneer in…
Read More...
Read More...